How to determine optimal treatment for de novo metastatic breast cancer
Fumiko Ladd Chino shared a post on X:
“Dr Jennifer Plichta, Duke Cancer Breast Surgical Oncology Grand Rounds MD Anderson Cancer Center today discussing how to determine optimal treatment for de novo metastatic breast cancer . Don’t count out MBC stageIV. We need better trials and better data collection!
Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer
Authors:
Fumiko Ladd Chino is an attending in Radiation Oncology at MD Anderson Cancer Center, who specializes in gynecological and breast cancers. She was also a caregiver for her husband Andrew Mark Ladd, PhD who died from cancer in 2007. She is a recipient of numerous awards, including ASCO Excellence in Equity Award (2022), Duke Radiation Oncology Award for Outstanding Clinical Research (2019), Duke University Hospital “Good Catch” Award (2018), Conquer Cancer Foundation of ASCO Merit Award (2018), Duke University School of Medicine Dean’s Recognition Award (2014) and Memorial Hermann Hospital, Texas Medical Center Volunteer of the Year Award (2009).
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023